-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
TextPharmaceutical Guanlan
On February 8, Kewang Pharma announced that its innovative antibody drug ES002 clinical trial application has obtained the implied license from the Center for Drug Evaluation (CDE) of the State Drug Administration of China, and will soon start a Phase 1 clinical trial in China
Published data show that CD39 is a key rate-limiting enzyme on the ATP-adenosine pathway and plays a crucial role in the immune regulation of the tumor microenvironment
ES002 promotes antitumor immune responses by targeting CD39
(Original abridged)